SNAP-Tag-Based Antibody-Drug Conjugates Targeting Epidermal Growth Factor Receptor 1, Epidermal Growth Factor...

Area of Science:

• Oncology
• Biotechnology
• Drug Development

Background:

• Ovarian cancer is a heterogeneous and aggressive gynecologic malignancy with limited treatment options.
• Antibody-drug conjugates (ADCs) offer targeted delivery of cytotoxic agents to cancer cells.
• Existing ADCs for ovarian cancer are limited, necessitating new therapeutic strategies.

Purpose of the Study:

• To develop and evaluate novel ADCs targeting key ovarian cancer biomarkers: EGFR, Her2, Trop2, and TF.
• To assess the binding, internalization, and cytotoxic efficacy of these ADCs in ovarian cancer models.

Main Methods:

• Construction of four ADCs using single chain variable fragments (scFvs) and monomethyl auristatin E (MMAE) via SNAP-tag technology.
• Validation of specific binding and internalization using flow cytometry and fluorescence microscopy.
• Assessment of dose-dependent cytotoxicity and apoptosis induction in four ovarian cancer cell lines.

Main Results:

• All four developed ADCs demonstrated specific binding and internalization into ovarian cancer cells.
• The ADCs exhibited potent and specific dose-dependent cytotoxicity against ovarian cancer cell lines.
• Apoptosis was induced at nanomolar concentrations, indicating significant anti-cancer activity.

Conclusions:

• The novel ADCs targeting EGFR, Her2, Trop2, and TF show promising preliminary efficacy against ovarian cancer.
• These ADCs possess encouraging characteristics for targeted cancer therapy.
• Further studies are warranted to fully validate the therapeutic potential of these antibody-drug conjugates.